Biotechnology company and drug delivery platform innovator
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that its wholly
owned subsidiary, Lexaria Nicotine LLC, has entered into a definitive agreement
with Altria Group Inc. (NYSE: MO) to fund the research and development of
Lexaria’s patented DehydraTECH technology. The company’s DehydraTECH enhances
the performance of ingestible products’ beneficial compounds across four
categories that include taste and smell, speed of action, bio-absorption and
bioavailability. According to the update, the partnership will explore
innovation in oral, reduced-risk nicotine products for consumers, as well as
potentially commercialize DehydraTECH for oral nicotine delivery. “This is an
incredible milestone for Lexaria Bioscience and our shareholders,” Lexaria
Bioscience CEO Chris Bunka said in the news release. “We are proud that Altria
has chosen to invest in our DehydraTECH technology and look forward to reaping
the benefits of working with a world-class partner. Together we have the
opportunity to change nicotine delivery and make a difference in the lives of
millions of consumers.”
To view the full press release, visit http://ibn.fm/eWaBc
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and quicker onset of lipophilic active molecules. Lexaria has
ten patents granted in the USA and in Australia and has filed over 50 patent
applications worldwide across ten patent families. Lexaria’s technology
provides more rapid delivery to the bloodstream; and important taste-masking
benefits, for orally administered bioactive molecules including cannabinoids,
vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
molecules. Lexaria Nicotine LLC is a United States domiciled, majority-owned
subsidiary of Lexaria Bioscience Corp., focused on reduced-risk nicotine
solutions www.LexariaNicotineco.com.
For more information, visit the company’s website at www.LexariaBioscience.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment